Overview

To Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients With Essential Hypertension and Primary Hypercholesterolemia

Status:
ENROLLING_BY_INVITATION

Trial end date:
2028-12-31

Target enrollment:

Participant gender:

Summary

A Multicenter, Randomized, Double-blind, Active-controlled, Parallel group, Phase 3 trial to Evaluate the Efficacy and Safety of Co-administrated HODO-2224-1 and HODO-2224-2 in Patients with Essential Hypertension and Primary Hypercholesterolemia

Phase:

PHASE3

Details

Lead Sponsor:

Hyundai Pharm

Treatments:

Amlodipine
candesartan
Ezetimibe